PALISADE CAPITAL MANAGEMENT, LP - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is and the CUSIP is 67011XAB9. A total of 34 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of NOVOCURE LTD
ValueSharesWeighting
Q3 2023$855,315
-0.7%
996,000
-0.4%
0.02%
+4.3%
Q2 2023$861,250
-1.2%
1,000,0000.0%0.02%
-4.2%
Q1 2023$871,681
-38.1%
1,000,000
-36.7%
0.02%
-40.0%
Q3 2022$1,408,000
+2.8%
1,580,0000.0%0.04%
+8.1%
Q2 2022$1,370,000
-4.7%
1,580,0000.0%0.04%
+12.1%
Q1 2022$1,438,000
+1.8%
1,580,000
+2.7%
0.03%
+13.8%
Q4 2021$1,412,0001,538,0000.03%
Other shareholders
NOVOCURE LTD shareholders Q2 2022
NameSharesValueWeighting ↓
DeepCurrents Investment Group LLC 46,391,000$42,604,0001.32%
Lombard Odier Asset Management (Europe) Ltd 171,980$15,871,0000.70%
WOLVERINE ASSET MANAGEMENT LLC 80,367,000$73,232,0000.68%
SHENKMAN CAPITAL MANAGEMENT INC 6,419,000$5,736,0000.39%
LINDEN ADVISORS LP 63,485,000$58,560,0000.36%
Ionic Capital Management LLC 3,000,000$2,771,0000.35%
SSI INVESTMENT MANAGEMENT LLC 5,859,000$5,354,0000.31%
Verition Fund Management LLC 33,485,000$30,766,0000.22%
Nicholas Investment Partners, LP 3,550,000$3,244,0000.20%
TFG Asset Management GP Ltd 3,000,000$2,769,0000.17%
View complete list of NOVOCURE LTD shareholders